Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.50 |
| ▸ | AVPR1A | P37288 | 8/20 | 0.50 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4372121 | 0.82 | NPY5R (0.46) | SIGMAR1NPY5RAVPR1A | |
| SCHEMBL4360871 | 0.82 | AVPR1A (0.54) | SIGMAR1NPY5RAVPR1A | |
| SCHEMBL3841581 | 0.82 | AVPR1A (0.54) | SIGMAR1NPY5RAVPR1A | |
| SCHEMBL8777675 | 0.80 | SIGMAR1 (0.61) | SIGMAR1NPY5RAVPR1A | |
| SCHEMBL8913424 | 0.80 | SIGMAR1 (0.62) | SIGMAR1NPY5RAVPR1A | |
| SCHEMBL10252829 | 0.77 | SIGMAR1 (0.58) | SIGMAR1NPY5RAVPR1ATNKSTNKS2 | |
| SCHEMBL9963268 | 0.76 | SIGMAR1 (0.58) | SIGMAR1NPY5RAVPR1A | |
| SCHEMBL14543925 | 0.76 | SIGMAR1 (0.70) | SIGMAR1NPY5RAVPR1A | |
| SCHEMBL8110392 | 0.76 | SIGMAR1 (0.58) | SIGMAR1NPY5RAVPR1A | |
| SCHEMBL6427482 | 0.75 | SIGMAR1 (0.56) | SIGMAR1NPY5RAVPR1ATNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589096-B2 | Azole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-15 | — | — | US | disclosed |
| EP-1566384-B1 | NOVEL AZOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2009-06-17 | — | — | EP | disclosed |
| US-20080188507-A1 | Novel azole derivatives | MSD K.K. (JP) | 2008-08-07 | — | — | US | disclosed |
| US-7365079-B2 | Azole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-29 | — | — | US | disclosed |
| EP-1566384-A1 | NOVEL AZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188507-A1 | Novel azole derivatives | NPY1R, NPY5R, NPY2R | SIGMAR1 1141/4885NPY5R 2/4885AVPR1A 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.